Agmatine is an endogenous decarboxylation product of arginine that has been previously shown to antagonize the Nmethyl-D-aspartate (NMDA) receptor and inhibit nitric-oxide synthase. Many neuropharmacological studies have shown that exogenous administration of agmatine prevents or reverses biological phenomena dependent on central nervous system glutamatergic systems, including opioid-induced tolerance, opioid self-administration, and chronic pain. However, the central nervous system (CNS) pharmacokinetic profile of agmatine remains minimally defined. The present study determined the spinal cord pharmacokinetics and acute pharmacodynamics of intrathecally administered agmatine in mice. After a single bolus intrathecal injection, agmatine concentrations in spinal cord (cervical, thoracic, and lumbosacral) tissue and serum were quantified by an isocratic high-performance liquid chromatography fluorescence detection system. Agmatine persisted at near maximum concentrations in all levels of the spinal cord for several hours with a half-life of approximately 12 h. Initial agmatine concentrations in serum were 10% those in CNS. However, the serum half-life was less than 10 min after intrathecal injection of agmatine, consistent with previous preliminary pharmacokinetic reports of systemically administered agmatine. The pharmacodynamic response to agmatine in the NMDA-nociceptive behavior and thermal hyperalgesia tests was assessed. Whereas MK-801 (dizocilpine maleate) inhibits these two responses with equal potency, agmatine inhibits the thermal hyperalgesia with significantly increased potency compared with the nociceptive behavior, suggesting two sites of action. In contrast to the pharmacokinetic results, the agmatine inhibition of both behaviors had a duration of only 10 to 30 min. Collectively, these results suggest the existence of a currently undefined agmatinergic extracellular clearance process in spinal cord.
Glutamatergic mechanisms modulate neuronal plasticity, a process proposed to govern neuropathic pain (Mao et al., 1992) , opioid tolerance (Trujillo and Akil, 1991; Tiseo and Inturissi, 1993) , drug addiction (Semenova et al., 1999) , and spinal cord injury (Faden and Simon, 1988 ). An outcome of the search for the endogenous ligand to the pharmacologically characterized imidazoline receptor was the identification of agmatine (decarboxylated arginine) in the mammalian central nervous system (CNS) receptor (Li et al., 1994) . The imidazoline receptor is associated with the cloned family of ␣ 2 adrenergic receptors in that the two receptor systems share a set of imidazoline ring-bearing ligands such as clonidine, moxonidine, rilmenidine, and idazoxan. Although agmatine does not have an imidazoline ring, as a clonidinedisplacing substance agmatine was included in this associated set of imidazoline receptor/␣ 2 ligands (Codd et al., 1995) ; it was later shown to also bind to ␣ 2 receptors, albeit without demonstrable activity (Pinthong et al., 1995) . Subsequent investigations extended the presumed agmatinergic targets and activity to include the observations that agmatine antagonizes NMDA receptors (Yang and Reis, 1999) and inhibits nitric-oxide synthase (Galea et al., 1996) , actions suggesting modulation of glutamatergic systems. Since the discovery of agmatine in mammalian CNS, we and others have studied the molecule in vivo and reported that it prevents the development of opioid tolerance (Kolesnikov et al., 1996; Fairbanks and Wilcox, 1997) , reverses the maintenance of pain resulting from inflammation, neuropathy, and spinal cord injury (Fairbanks et al., 2000) , and attenuates escalation of opioid self-administration (Morgan et al., 2002) . Despite the extensive glutamate literature (Ͼ74,000 journal articles since 1966), comparatively few studies have been performed with agmatine (ϳ600 journal articles).
In the previous reports examining exogenously administered agmatine on in vivo systems, agmatine sulfate has been administered primarily by systemic routes, including intravenous, subcutaneous, intraperitoneal, and intrarenal administration. The doses, species, dependent measures, and outcomes from greater than 50 such in vivo studies have recently been reviewed (Nguyen et al., 2003) . The effective systemic agmatine doses that elicit therapeutic results in these animal models exhibit a wide range (10 -400 mg/kg); 100 mg/kg has been the most frequently applied effective systemic dose of agmatine. Many of these studies assert a central site of action for agmatine. However, agmatine is a cation at physiological pH and therefore should not readily cross the blood-brain barrier. Furthermore, an agmatinergic blood-brain barrier transport system has yet to be definitively characterized. In support of the proposal that agmatine exerts its effects through a central site of action, a number of studies have applied agmatine through central routes of administration, including intracerebroventricular (for a complete list, see Nguyen et al., 2003) and intrathecal (Fairbanks and Wilcox, 1997; Horvath et al., 1999; Fairbanks et al., 2000; Hou et al., 2003) . Although these pharmacological studies provide proof-of-principle for agmatinergic modulation of many centrally mediated plasticity-requiring phenomena, minimal information is available regarding the pharmacokinetics of agmatine in the serum or the CNS. Two preliminary studies report mouse spinal cord (Nguyen et al., 2003 ) and brain (Piletz et al., 2003) recovery of agmatine after systemic administration of agmatine. Piletz et al. (2003) also reported a preclinical study of CSF agmatine recovery after systemic administration (30 mg/kg i.v.) in a single retired experimental nonhuman primate. Although these results also provide evidence for agmatine's pharmacological action within the CNS, a full pharmacokinetic evaluation of agmatine in CNS has yet to be reported. Such information is important in defining the therapeutic utility of the molecule as well as its role in CNS processing. The objective of this study was to directly compare spinal cord pharmacokinetics with pharmacodynamic responses to intrathecally administered agmatine in a murine model of acute activation of the neuronal NMDA receptor-nitric-oxide synthase system (Kitto et al., 1992) .
Materials and Methods
Animals. Experimental subjects included Institute of Cancer Research (ICR) mice (21-30 g; Harlan, Madison, WI). Subjects were housed in groups of eight in a temperature-and humidity-controlled environment, maintained on a 12-h light/dark cycle, and they had free access to food and water. These experiments were approved by the University of Minnesota Institutional Animal Care and Use Committee.
Chemicals. MK-801 (dizocilpine maleate) was obtained from Merck Sharpe & Dohme (Rahway, NJ), 7-nitroindazole (7-NINA) sodium salt was from Tocris Cookson Inc. (Ellisville, MO). Agmatine sulfate and NMDA were purchased from Sigma Chemical Co. (St. Louis, MO). All drugs were dissolved in 0.9% saline.
Intrathecal Injection. Agmatine was administered intrathecally (i.t.) in conscious mice according to the method of Hylden and Wilcox (1980) as described in detail by Fairbanks (2003) . Briefly, the pelvic girdle (ileac crest) of the mouse is gripped firmly by the thumb and forefinger of the injectors' nondominant hand. The skin above the ileac crest is pulled tautly to create a horizontal plane where the needle is inserted. The needle is a 30-gauge, 0.5-inch sterile disposable needle connected to a 50-l Luer-hub Hamilton syringe. All injections were delivered in 5 l of vehicle, a frequently used volume in pharmacodynamic studies of intrathecally delivered agents in mice. Notably, some preliminary experiments were performed to evaluate the CNS recovery of agmatine (120 nmol) at 3 and 10 min after intrathecal injections of 1-and 2.5-l volumes. However, for both the 1-and 2.5-l volumes, spinal agmatine recovery was low at 3 min (Ͻ10 pmol/mg) and generally below the limit of detection at 10 min. In contrast, the 5-l volume yielded sufficient concentrations over time to assess the pharmacokinetic parameters of agmatine in spinal cord.
NMDA-Induced Nociceptive Behavioral Responses. NMDA responses were induced by a single intrathecal injection (0.3 nmol) of NMDA according to the method of Aanonsen and Wilcox (1987) . The animal's scratching and biting responses in the first minute after injection are counted. After 1 min, NMDA no longer produces the scratching and biting response.
NMDA-Induced Thermal Hyperalgesia. A warm water (49°C) tail immersion test for NMDA-induced thermal hypersensitivity (adapted from the radiant heat method of Kitto and Wilcox, 1992) followed 3 to 5 min after injection of NMDA. Three or 5 min after injection with NMDA (0.3 nmol), the animals show a decrease in latency to tail-flick (1-2 s) in response to applied noxious heat (49°C) relative to their baseline and also to saline-injected controls. Other signs of irritation or discomfort (vocalization and motor impairment) are not present. This test is conducted immediately after and in the same animals in which the NMDA nociceptive scratching and biting behaviors are counted. Since the behaviors occur in the first minute and cease thereafter, it is then possible to conduct a test of thermal hyperalgesia at 3 to 5 min after injection of NMDA.
Dose-Response Analysis. The pharmacological parameters presented in Table 1 were calculated using the using the pharmacological statistics software FlashCalc version 4.3.2 (Dr. Michael Ossipov, University of Arizona, Tucson, AZ) (Wells et al., 2001; Xie et al., 2005) , which is based on the methods described by Tallarida and Murray (1987) and Tallarida (2000) . A minimum of three doses was used for each drug.
Spinal Distribution of Agmatine in ICR Mice. In intrathecal dosing experiments, the mice received 120 nmol of agmatine as a single intrathecal dose. At different times after the injection (1, 3, 10, 30, 60, 180, and 360 min; 24, 48, 72 , and 168 h; n ϭ 5 or more for each time point), trunk blood was collected for serum analysis. Spinal cords were extruded by hydraulic pressure (using cold phosphatebuffered saline) and quick-frozen on dry ice. Spinal cords were dissected into cervical, thoracic, and lumbosacral sections using the cervical and lumbosacral enlargements as indicators. Serum and tissue were stored at Ϫ80°C until HPLC analysis. In a smaller study, mice were given 60 nmol of agmatine as the intrathecal dose, and tissue and serum were extracted at 1, 10, and 30 min (n ϭ 4 -5 per time point). This is the same dose that gives maximum effect in the NMDA nociceptive and thermal hyperalgesia assay. HPLC Analysis. The HPLC protocol is based on two methods for agmatine determination (Raasch et al., 1995; Feng et al., 1997) and modified to use naphthalene dicarboxaldehyde as the derivatization agent (deMontigny et al., 1987) . Tissue extracts were concentrated under vacuum and suspended in 100 l of borate buffer, pH 9.4; NaCN (40 l; 0.025 M) was added, followed by naphthalene dicarboxaldehyde (100 l; 0.05 M) in MeOH, which was allowed to react at room temperature for 20 min. Derivatization of agmatine with naphthalene dicarboxaldehyde produces a highly fluorescent molecule of high stability. Five to 10 l of the reaction mixture were injected onto a 250 ϫ 4.6-mm Alltech Nucleosil C8 10-m HPLC cartridge and eluted with 80% ACN in a buffer prepared by dissolving 3.42 g of KH 2 PO 4 and 4.32 g of K 2 HPO 4 in 1 liter of HPLC-grade H 2 O, pH 6.81, at a flow rate of 1.5 ml/min. Fluorescence of the agmatine derivative was recorded over time using an excitation wavelength of 249 nm and an emission wavelength of 466 nm. External agmatine standards were used to calculate the concentration of agmatine in tissue and plasma. Samples exhibiting peak areas outside of the linear range of the agmatine standard curve were diluted accordingly and injected again for quantification.
Pharmacokinetic Analysis. In vivo pharmacokinetic parameters (C max , t 1/2, AUC cord , and AUC serum ) were determined using WinNonlin version 3.1. Noncompartmental analysis, WinNonlin NCA 201, with linear/log trapezoidal rule was used for determination of area under the curves, AUC 0 -ϱ . Predicted elimination phases for each pharmacokinetic profile were assigned and fitted using a WinNonlin log-transformed linear regression with 1/y weighting.
Results
Antagonism of NMDA-Induced Thermal Hyperalgesia. Intrathecal injection of NMDA (0.3 nmol) produces two mechanistically distinct behaviors. First, a scratching and biting response directed to the hindlimbs is evident for the first minute postinjection, ceasing thereafter. Second, within 3 to 5 min, a transient thermal hyperalgesia develops, subsiding within 30 min postinjection. These two behaviors were dose dependently inhibited by coadministration of NMDA with MK-801. Figure 1A illustrates a comparison of MK-801-induced inhibition of the nociceptive behavior and inhibition of the thermal hyperalgesia. In these studies, the nociceptive behavior and the thermal hyperalgesia were measured consecutively (time-wise) in the same subjects. In this particular experiment, NMDA (0.15 nmol i.t.) evoked an average of 40 behaviors (S.E.M. Ϯ 1.9; n ϭ 6) within the 1st min; saline injected i.t. evoked no such response. The average baseline tail-flick latency (4.6 Ϯ 0.09; n ϭ 36) was reduced by 1.6 s (3.1 Ϯ 0.16; n ϭ 6) in mice that received NMDA (0.15 nmol i.t.). Coadministration of the noncompetitive NMDA receptor antagonist MK-801 with NMDA dose dependently reversed both the nociceptive behaviors and the thermal hyperalgesia (Fig. 1A) . The potency of MK-801 was comparable for antagonism of the nociceptive behavior and the thermal hyperalgesia ( Fig. 1A ; Table 1 ) with ED 50 values that have overlapping confidence intervals, which indicates that MK-801 likely inhibits both behaviors by a similar mechanism (presumably NMDA receptor antagonism).
Unlike MK-801, the selective neuronal nitric-oxide synthase inhibitor 7-NINA dose dependently inhibited the thermal hyperalgesia but had no impact on the nociceptive behavior (also measured within the same mice) ( Fig. 1B ; Table  1 ). These results illustrate that the mechanisms underlying the two behaviors can be distinguished pharmacologically. In contrast to both MK-801 and 7-NINA, coadministration of agmatine with NMDA dose dependently inhibited both the nociceptive behavior and the thermal hyperalgesia at significantly different potencies (Fig. 1C) . Agmatine inhibited the nociceptive behavior with 21-fold lower potency than for the thermal hyperalgesia (Table 1) ; it is noteworthy that the confidence intervals (CIs) of these dose-response curves are nonoverlapping. Additionally, agmatine seemed to act as a partial antagonist against the nociceptive behavior, but a full antagonist against the thermal hyperalgesia. The differential pharmacology between the two dependent measures suggests two separate sites of action for agmatine in the spinal cord. These experiments were all replicated with similar outcomes; a replication of the agmatine experiment was reported previously (Fairbanks et al., 2000) . There was no evidence of adverse or toxic effects of agmatine at any of the doses evaluated.
Time-Effect Course of Agmatine-Mediated Inhibition of NMDA-Evoked Behavior and Thermal Hyperalgesia. Intrathecally administered agmatine (60 nmol i.t.) consistently and reproducibly partially antagonized NMDAevoked nociceptive behavior and fully inhibited the thermal hyperalgesia when coadministered with NMDA. To determine the time-effect relationship of agmatine in these two pharmacodynamic measures, the most effective dose (60 nmol i.t.) of agmatine (or saline) was intrathecally administered as a pretreatment 1, 3, 10, 30, and 60 min before the administration of NMDA (Fig. 2) . In both measures, the inhibitory effect of agmatine persisted at 1-, 3-, and 10-min pretreatment. The effect was not present at 30 or 60 min. These results indicate the pharmacodynamic activity of agmatine may be limited to a relatively short time window in acutely measured behavior such as this model. These experiments were replicated with similar outcomes.
Time-Concentration Profile of Agmatine in Spinal Cord and Serum. Intrathecally administered agmatine (120 nmol) seemed to distribute throughout all three levels of the cord without a detectable absorption phase (Figs. 3 and  4) . Concentrations comparable with the C max for each level (lumbosacral, 540 Ϯ 89 pmol/mg; thoracic, 715 Ϯ 130 pmol/ mg; and cervical tissue, 250 Ϯ 31 pmol/mg) were detected out to 6 h postinjection. A significant decline in concentration (relative to the C max ) was observed at 24, 48, and 72 h. By 7 days postinjection, the agmatine concentration in the spinal cord tissue was below the limit of detection. Agmatine was detected in serum at concentrations of approximately 10% that observed in CNS tissue by 1-min postinjection but declined rapidly ( Fig. 3; Table 1 ). Serum agmatine concentrations were below the limit of detection by the 180-min time point; consequently, this and subsequent times were omitted from analysis.
In a more restricted study (n ϭ 4 -5 per group), a dose of 60 nmol of agmatine was injected (i.t.), and tissue and serum were collected at selected time points (1, 10, and 30 min). The C max values of agmatine in lumbosacral (230 Ϯ 34 pmol/mg), thoracic (340 Ϯ 68 pmol/mg), and cervical tissue (120 Ϯ 52 pmol/mg) at this dose were approximately half those quantified at the respective spinal levels after the 120-nmol dose (Table 1) , as would be expected for dose-independent pharmacokinetics. Additionally, in this instance, brainstem samples also were collected and evaluated; the C max in brainstem was 58 Ϯ 2.0 pmol/mg. As in the samples collected for the 120-nmol dose, the samples from the 60-nmol study showed a clear rostral decline in concentrations from lumbosacral to cervical to brainstem, as would be expected for a molecule that is largely retained within the CNS with minor redistribution to the systemic circulation.
To determine whether the source of the serum agmatine was redistribution from the intrathecal space to the vasculature or from possible leakage to the systemic circulation from the musculoskeletal tissue surrounding injection site, we conducted a side-by-side comparison of serum collected from mice injected with agmatine (120 nmol/5 l) either i.t. or intramuscularly (i.m.) at the 1-min time point. The i.m. route jpet.aspetjournals.org was included to control for the possibility that leakage from the intrathecal injection into the muscle surrounding the spinal column could account for the presence of agmatine in the serum. Intrathecally injected agmatine resulted in significantly greater serum concentrations of 12 Ϯ 2.0 pmol/l (n ϭ 8) compared with agmatine serum concentrations of 3.5 Ϯ 0.76 pmol/l (n ϭ 8) from i.m. injection (Student's t test; p Ͻ 0.01). These data support the hypothesis that the source of the serum agmatine represented in Figs. 3 and 4 is most likely to be the agmatine delivered to the intrathecal space (rather than leakage to the musculoskeletal area surrounding the column) and subsequently redistributed to the systemic circulation via the CNS microvasculature.
For pharmacokinetic comparison with the i.t. injections, a set of systemic administrations (n ϭ 5-6 per group), with a dose of 100 mg/kg (ϳ11 mol/mouse) agmatine was injected intraperitoneally (i.p.) or intravenously (i.v.) by tail vein delivery, and tissue and serum were collected at selected time points. The C max value of i.p.-delivered agmatine in serum was 907 Ϯ 212 pmol/l) at 1-min postinjection and declined to 12 Ϯ 5 (S.D.) pmol/l by 180 min. Agmatine was undetectable in spinal cord tissue under these conditions at this dose given by the i.p. route of administration. In contrast, the C max value of i.v.-delivered agmatine in serum was 4020 Ϯ 1220 (S.D.) pmol/l at 1-min postinjection and declined to 42 Ϯ 17 pmol/mg by 60 min. Agmatine was detectable in spinal cord tissue after i.v. administration with a maximum concentration (58 Ϯ 7 pmol/mg) at 1-min postinjection, which declined to 17 Ϯ 9 pmol/mg by 30 min. These data confirm that although CNS levels may be very limited, agmatine is detectable in CNS after i.v. administration of 100 mg/kg, a dose commonly used in pharmacological studies of exogenously applied agmatine (Nguyen et al., 2003) .
Pharmacokinetic Parameter Estimates for Intrathecally Administered Agmatine. Noncompartmental analysis of mean concentrations revealed decreasing agmatine exposure, with increasing distance from the site of the intrathecal injection (Table 2) . Less than a 3-fold difference was seen in agmatine exposure between the most separated spinal cord regions, suggesting widespread spinal cord distribution of agmatine upon intrathecal injection. AUC ratios between spinal cord and serum were more than 1000-fold higher for all spinal cord regions (supporting a centrally mediated agmatine effect in the behavioral assays discussed in Introduction). The half-lives were similar in all spinal cord regions ranging from t 1/2 ϭ 11.1 to 12.6 h, in contrast to the serum half-life, t 1/2 ϭ 6.9 min. In the restricted lower dose experiment (60-nmol injection), the serum t 1/2 was comparable to the 120-nmol dose experiment.
Discussion
Increasing evidence suggests that decarboxylated arginine, agmatine, operates as a novel neurotransmitter and/or neuromodulator in mammals (Reis and Regunathan, 1998) . Asserting that claim requires, among other things, testing the hypothesis that, when administered exogenously, agmatine produces pharmacological effects comparable with the proposed physiological effects of the putative endogenous molecule (Kandel et al., 2000) . Since its discovery in the CNS (Li et al., 1994) , there have been approximately 60 studies evaluating a variety of physiological effects produced by exogenous administration of agmatine. Most of these studies applied a systemic (rather than a central) route of administration. Despite the positive pharmacodynamic results demonstrated by many of these reports, the duration of high serum or plasma agmatine levels after systemic delivery is very short (Raasch et al., 2002; Nguyen et al., 2003; Piletz et al., 2003) . Furthermore, CNS levels of agmatine after standard systemic doses have had limited description (Raasch et al., 2002; Nguyen et al., 2003; Piletz et al., 2003) . The pharmacokinetics of CNS agmatine have not been evaluated. To begin to address these issues, the present study directly compared spinal cord pharmacokinetic parameters with acute pharmacodynamic responses to agmatine after a single intrathecal injection in mice. Pharmacodynamic Studies of Spinal Agmatine. We have previously observed that intrathecally administered agmatine (decarboxylated arginine) inhibits carrageenanevoked mechanical hyperalgesia (Fairbanks et al., 2000) , prevents morphine-induced acute tolerance (Fairbanks and Wilcox, 1997) , and reverses neuropathy-induced hyperalgesia (Fairbanks et al., 2000) in mice. These behavioral models of plasticity require 3-, 8-, and 24-h induction periods, respectively, and all have shown a dependence on the NMDA receptor/NOS cascade. These induction periods inherently contain an induction phase and a maintenance phase, the borders of which are not clearly defined. Therefore, it is challenging to temporally pinpoint the action of a modulator (e.g., MK-801, L-NAME, or agmatine). In other words, the point at which the modulator exerts its effect is not clearly defined. We have also observed that agmatine acutely inhibits both the nociceptive scratching and biting behavior (NMDA receptor-dependent) and the thermal hyperalgesia (NMDA receptor-and NOS-dependent) that arises when NMDA is directly injected into the intrathecal space (Fairbanks et al., 2000) (Fig. 1C) . These NMDA-induced responses take place on 5-s to 5-min time frames, respectively. Compared with the models of longer induction, maintenance, and duration described above, these time periods can be more comprehensively parsed for timing of action. We therefore evaluated whether agmatine could differentially inhibit two phases of a rapid induction model of behavioral plasticity (NMDA receptor/NOS cascade behavioral and thermal hyperalgesia) to determine whether the temporal characteristics of this model are useful for examining agmatine action in the CNS.
Antagonism of NMDA-Induced Nociceptive Behavior and Thermal Hyperalgesia. Agmatine has been previously shown to antagonize NMDA receptors (Yang and Reis, 1999; Fairbanks et al., 2000) and inhibit NOS (Auguet et al., 1995; Galea et al., 1996) . Because induction of neuronal NOS follows NMDA-induced activation, we compared the ability of agmatine to inhibit two NMDA-induced behavioral sequelae. NMDA (0.3 nmol) delivered intrathecally produces a scratching and biting behavior that persists for about a minute after injection. This behavior is dose dependently antagonized by coinjection of NMDA with a variety of classically defined noncompetitive (MK-801, dextromethorphan, ketamine, and memantine), competitive (LY235959), NR2B subunit-selective (ifenprodil) NMDA receptor antagonists (Fairbanks et al., 2000) . Like the NMDA receptor antagonists, agmatine dose dependently inhibited the NMDA-evoked behavior, although with a lower potency (Fairbanks et al., 2000; Fig. 1C) . The rank order of potency for antinociceptive activity of NMDA antagonists in this model was LY235959 Ͼ ketamine ϭ ifenprodil ϭ mementaine ϭ aminoguanidine Ͼ MK-801 Ͼ agmatine. We also tested agmatine in a model of NMDA-evoked thermal hyperalgesia. This behavior is dependent on three steps: NMDA receptor activation, NOS activation, and extracellular diffusion of nitric oxide (Kitto and Wilcox, 1992) . The thermal hyperalgesia response was inhibited by the noncompetitive NMDA receptor antagonist, MK-801, with approximately the same potency observed for prevention of the nociceptive behaviors. The equal potency of MK-801 in both measures would be expected, since the NMDA receptor operates upstream of NOS, such that blockade of NMDA receptor should prevent activation of NOS.
Previous studies have shown that intrathecal delivery of NOS inhibitors (e.g., L-NAME) prevents the development of NMDA-induced thermal hyperalgesia in rodents (Kitto et al., 1992; Malmberg and Yaksh, 1993) , but it does not affect the NMDA-evoked nociceptive behavioral component of the response in mice (Kitto et al., 1992; Fairbanks et al., 2000) . This would also be expected since the NOS inhibitors, acting downstream of NMDA receptors, should not affect their initial activation. The present demonstration that the selective neuronal NOS inhibitor 7-NINA (Moore et al., 1993 ) also inhibited development of the thermal hyperalgesia without affecting the behavior (Fig. 1B) is consistent with this inference and our previous results using the nonselective NOS inhibitor L-NAME (Kitto et al., 1992; Fairbanks et al., 2000) ; the 7-NINA results suggest that the behavior may depend upon neuronal NOS. However, further studies would be needed to evaluate the potential relative contributions of inducible NOS and endothelial NOS.
Like MK-801, agmatine dose dependently inhibited both the nociceptive behavior and the thermal hyperalgesia. However, a notable difference was that agmatine inhibited the thermal hyperalgesia with significantly higher potency compared with antagonism of the nociceptive behaviors measured in the same subject. Additionally, agmatine fully inhibits the thermal hyperalgesia but only partially antagonizes the nociceptive behavior. These differences are consistent with previous reports that agmatine acts at both NOS (Galea et al., 1996) and NMDA receptors (Yang and Reis, 1999) . In this case, perhaps blockade at both sites acts in an autopotentiating manner. Since we have previously observed (Fairbanks et al., 2000) that agmatine exhibits relatively long-term effectiveness in two models of carrageenan-evoked hyperalgesia (on the order of hours) and in two chronic models of mechanical hyperalgesia (dynorphin-and spinal nerve ligation-induced, on the order of weeks), we evaluated the time course for agmatine in both NMDA-evoked nociceptive behavior and thermal hyperalgesia. Interestingly, the effectiveness of agmatine as a pretreatment to the NMDA diminished relatively rapidly, on the order of minutes. This result would imply either a rapid clearance of agmatine from the CNS or a redistribution of agmatine from its pharmacological targets (e.g., clearance from the synapse or intracellular proximity to NOS). The pharmacokinetic data support the latter argument. However, it is evident that agmatine residence in the CNS is significantly longer than its ability to inhibit acute NMDA-evoked pharmacodynamic events.
Pharmacokinetic Studies. After a single intrathecal bolus delivery of agmatine, serum and spinal cord tissue (lumbo-sacral, thoracic, and cervical levels) were collected and analyzed by HPLC. At 1-min postinjection, agmatine was present in the serum at its peak concentration (C max ), which means that a small but significant component of agmatine was redistributed to the systemic circulation rapidly (if not immediately) after injection. Consistent with other preliminary reports evaluating the half-life of agmatine in serum or plasma after its systemic injection (Raasch et al., 2002; Nguyen et al., 2003; Piletz et al., 2003) , elimination of agmatine from serum occurred rapidly, on the order of minutes. In contrast, agmatine reached its maximum concentration in the spinal cord at all levels by 60 min and persisted at levels comparable with the peak concentration as long as 6 h. This finding is consistent with a preclinical pilot study where a retired experimental monkey received agmatine intracerebroventricularly (300 g/kg); CSF sampled at 24 h postinjection showed agmatine in the 300 M range. Therefore, two independent studies in two species show that exogenous agmatine persists in the CNS (CSF and spinal cord tissue) on the order of hours to days rather than minutes to hours as is observed in serum. The fact that intrathecally administered agmatine persists in mouse spinal cord tissue on the order of hours to days is consistent with the longer pharmacodynamic efficacy observed in the inflammation and chronic pain models. However, it contrasts with the acute pharmacodynamic effects presented in Figs. 1 and 2 . Together, these observations imply a CNS cellular uptake and storage system for agmatine as yet to be defined.
In conclusion, previous reports have shown that exogenously applied agmatine inhibits NMDA receptor/NOS-dependent phenomena (e.g., persistent pain and opioid tolerance) with an either documented or implied duration of action on the order of hours to days. However, this study shows that in one model of acutely induced NMDA-evoked behavior and hyperalgesia agmatine's duration of action is on the order of minutes. These results would on the surface seem incongruent with the previous reports except that the spinal pharmacokinetic data presented here indicate a clear prolonged duration of agmatine residence within spinal tissue, consistent with previous pharmacodynamic studies; these pharmacodynamic results stand in contrast to serum levels and kinetics. The short duration of agmatine's action in the NMDA-evoked behavior and hyperalgesia model together with its long duration of residence in the spinal cord tissue suggests yet unidentified mechanisms of retention in and clearance from its pharmacological targets. Further studies are needed to clarify this aspect of agmatinergic neuropharmacology.
